Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell...

  • Monday, August 20, 2012, 8:40 AM ET
    Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell lymphoma, a rare type of non-Hodgkin's lymphoma, enrolls its 5th patient, thereby triggering a second milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (First payment)
Track new comments on this story

This news story has 2 comments:

  •  
    Been waiting for it to sell off at least a little, so I can get a little more! Still waiting!

    I guess options the brstw ay right now.

    The Greek
    20 Aug 2012, 09:01 AM Reply Like
  •  
    Been waiting for PCYC to sell of a little to get a little more. That hasn't worked! The train gas left the station!
    Guess options best way!
    20 Aug 2012, 09:02 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »